Cov-Secure is the first blood-based Covid-19 diagnostic test

A simple blood sample offers an unprecedent negative predictive value.

Using this test, negative subjects know they are Covid-free.

A supplement to RT-PCR

Cov-Secure offers a better sensitivity to the Covid-19 reference test (RT-PCR) in symptomatic patients.

There are two ways to use the Cov-Secure test:

  • either at the same time as the RT-PCR, to lower the false-negative rate of the diagnostic

  • or as a first-line test for Covid-Free zones (negative subjects will likely not have the Covid-19)

A blood-based test

Unlike other Covid-19 diagnostic tests (including RT-PCR, antigenic and RT-Lamp), Cov-Secure is blood based. There is no variability in the results due to the sample collection.

Indeed a major part of the false-negative results of the RT-PCR and antigenic tests is due to the naso-pharyngeal sample collection.

Using the Cov-Secure test, based on a standard blood-draw, there is no such variability, leading to a much safer test result.

Two use cases

  • either as a confirmation of RT-PCR, reducing false-negative

  • or as a first-line test, reducing RT-PCR by 80%

Comparison table 1 showing different methods for testing for fibrosis

2 components, 1 score

Cov-Secure combines two standard biomarkers

  • Apolipoprotein A1
  • Haptoglobin

These markers are weighted depending on the patient's age and sex.

Tests may take place in any local medical test laboratory that is compliant with BioPredictive's technical recommendations.

There is no need to fast to have Cov-Secure done

Where to do the test   Technical Recommendations  


  1. Houot M, Ngo Y, Munteanu M, Marque S, Poynard T. Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B. Aliment. Pharmacol. Ther. 2016;43:1. abstract article